Nex­tech leads a $56M round for the Rev­o­lu­tion's move in­to the clin­ic

Third Rock start­up Rev­o­lu­tion Med­i­cines is open­ing a new chap­ter in its his­to­ry to­day with a $56 mil­lion ven­ture round aimed at mov­ing its first ex­per­i­men­tal ther­a­py in­to the clin­ic.

The Red­wood City, CA-based biotech launched three years ago with a $45 mil­lion A round de­signed to get them start­ed on build­ing a plat­form tech around a strat­e­gy aimed at ex­ploit­ing “na­ture’s se­lec­tion of mol­e­cules to bind to tar­gets that couldn’t be bound to syn­thet­i­cal­ly,” as CEO Mark Gold­smith puts it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER